Abstract
To prospectively investigate morphologic and functional changes after intravitreal bevacizumab for persistent diffuse and clinically significant diabetic macular edema. In total, 26 eyes in 26 patients were treated with three intravitreal injections of bevacizumab (Avastin™) given at 4-week intervals. Study parameters included: visual acuity (VA), perceived visual improvement, central macular thickness as measured by Spectralis OCT, macular sensitivity and fixation pattern as measured by MP-1 microperimetry, and the incidence of ocular and systemic side-effects. At the time of follow-up, 76.9 % of eyes showed a significant improvement in VA (p = 0.012), 38.4 % showed a one-line improvement on the ETDRS chart compared with VA at day 0, 30.7 % showed a two-line improvement, and 7.6 % showed at least a three-line improvement. The mean central macular thickness was 447 microns at day 0 and 311.1 microns at follow-up (p = 0.003). The mean baseline macular sensitivity, by MP-1 microperimetry, was 8.29 dB; at follow -up, macular sensitivity had improved to 14.26 dB (p = 0.025). These results support further controlled trials on the efficacy of intravitreal bevacizumab in treating diabetic macular edema. Microperimetry and OCT are important tools in managing diabetic patients, providing a detailed study of the macular region, particularly when it is necessary to monitor the morphological and functional outcome after various interventions. A good correlation between retinal sensitivity and perceived visual performance was found.
Similar content being viewed by others
References
Lopes de Faria JM, Jalkh AE, Trempe CL, McMeel JW (1999) Diabetic macular oedema: risk factors and concomitants. Acta Ophtalmol Scand 77:170–175
Joussen A, Smyth N, Niessen C (2007) Pathophysiology of diabetic macular edema. In: Lang GE (ed) Diabetic retinopathy. Dev ophthalmol, vol 39. Karger, Basel, pp 1–12
Marmor MF (2000) Macular edema. Kluver Academic publisher, Dordrech, pp 35–47
Venkatesh P, Abhas Z, Garg S (2006) Prospective optical coherence tomographic evaluation of the efficacy of oral and posterior subtenon corticosteroids in patients with intermediate uveitis. Graefes Arch Clin Exp Ophthalmol 245:59–67
Vujosevic S, Midena E (2006) Diabetic retinopathy. In: Midena E (ed) Perimetry and the fundus: An introduction to microperimetry. Slack Incorporated, Thorofare, pp 53–58
Early Treatment Diabetic Retinopathy Study Research Group (1985) Photocoagulation for diabetic macular edema. Early treatment diabetic retinopathy study report number 1. Early treatment diabetic retinopathy study research group. Arch Opthalmol 103:1796–1806
Lee CM, Olk RJ (1991) Modified grid laser photocoagulation for diffuse diabetic macular edema. Long-term visual results. Ophthalmology 98:1594–1602
Fujikado T, Asounuma S, Ohji M, Kusaka S, Hayashi A, Ikuno I, Kamei M, Oda K, Tano Y (2002) Reading ability after macular translocation surgery with 360-degree retinotomy. Am J Ophthamol 85:877–882
Fujii GY, De Juan E Jr, Humayun MS et al (2003) Characteristics of visual loss by scanning laser ophthalmoscope microperimetry in eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Am J Ophthalmol 136:1067–1078
Grenga P, Lupo S, Domanico D, Vingolo EM (2008) Efficacy of intravitreal triamcinolone acetonide in long standing diabetic macular edema. A microperimetry and optical coherence study. Retina 28:1270–1275
Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E, Baumal C (2002) Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 109:920–927
Ooi CG, Hardy KJ (1999) Treatment of severe proliferative retinopathy and diabetic maculopathy. Diabetes Metab Res Rev 15:373–377
Haritoglou C, Kook D, Neubauer A, Wolf A, Proglinger S, Strauss R et al (2006) Intravitraeal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 26:999–1005
Kumar A, Sinha S (2007) Intravitreal bevacizumab (Avastin) treatment of diffuse diabetic macular edema in an Indian population. Indian J Opthamol 55:451–455
Kook D, Wolf A, Kreutzer T, Neubauer A, Strauss R, Ulbig M, Kampik A, Haritoglou C (2008) Long-term effect of intravitreal bevacizumab (Avastin) in patients with chronic diffuse diabetic macular edema. Retina 28:1053–1060
Diabetic Retinopathy Clinical Research Network (2007) A phase 2 randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthamology 114:1860–1867
Starita C, Patel M, Katz B, Adamis AP (2007) Vascular endothelial growth factor and the potential therapeutic use of pegaptanib (Macugen) in diabetic retinopathy. Dev Ophthalmol 39:122–148
Chun DW, Heier JS, Topping TM et al (2006) A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology 113:1706–1712
Nguyen QD, Tatlipinar S, Shah SM et al (2006) Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol 142:961–969
Roh MI, Byeon SH, Kwon OW (2008) Repeated intravitreal injection of bevacizumab for clinically significant diabetic macular edema. Retina 28:1314–1318
Massin P, Girach A, Erginay A, Gaudric A (2006) Optical coherence tomography: a key to future management of patients with diabetic macular edema. Acta Ophthamol Scand 84:466–474
Moreira RO, Trujillo FR, Meirelles RMR, Ellinger VC, Zagury L (2001) Use of optical coherence tomography (OCT) and indirect ophthalmoscopy in the diagnosis of macular oedema in diabetic patients. Int Ophthalmol 24:331–336
Karacorlu M, Ozdemir H, Senturk F, Karacorlu SA, Uysal O (2010) Macular function after intravitreal triamcinolone acetonide injection for diabetic macular oedema. Acta Ophthalmol 88(5):558–563
Rohrschneider K, Bultmann S, Gluck R, Kruse Fe, Fendrich T, Volcker He (2000) Scanning laser ophthalmoscope fundus perimetry before and after laser photocoagulation for clinically significant diabetic macular edema. Am J Ophthalmol 129:27–32
Vujosevic S, Mdena E, Pilotto E, Radin PP, Chiesa L, Cavarzeran F (2006) Diabetic macular edema: correlation between microperimetry and optical coherence tomography findings. Invest Ophthamol Vis Sci 47:3044–3051
Chen FK, Patel PJ, Xing W, Bunce C, Egan C, Tufail AT, Coffey PJ, Rubin GS, Da Cruz L (2009) Test-retest variability of microperimetry using the Nidek MP1 in patients with macular disease. Invest Ophthalmol Vis Sci 50:3464–3472
Weingessel B, Sacu S, Vecsei-Marlovits PV, Weingessel A, Richter-Mueksch S, Schmidt-Erfurth U (2009) Interexaminer and intraexaminer reliability of the microperimeter MP-1. Eye 23:1052–1058
Lardenoye CWTA, Probst K, DeLint PJ, Rothova A (2000) Photoreceptor function in eyes with macular edema. Invest Ophthalmol Vis Sci 41:4048–4053
Ota M, Tsujikawa A, Murakami T, Yamaike N, Sakamoto A, Kotera Y, Miyamoto YK, Kita M, Yoshimura N (2008) Foveal photoreceptor layer in eyes with persistent cystoid macular edema associated with branch retinal vein occlusion. Am J Ophthalmol 145(2):273–280
Oishi A, Otani A, Sasahara M, Kojima H, Nakamura H, Kurimoto M, Yoshimura N (2009) Photoreceptor integrity and visual acuity in cystoid macular oedema associated with retinitis pigmentosa. Eye 23:1411–1416
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Malagola, R., Spinucci, G., Cofone, C. et al. Prospective microperimetry and OCT evaluation of efficacy of repeated intravitreal bevacizumab injections for persistent clinically significant diabetic macular edema. Int Ophthalmol 33, 261–267 (2013). https://doi.org/10.1007/s10792-012-9685-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10792-012-9685-3